3.52Open3.52Pre Close0 Volume13 Open Interest15.50Strike Price0.00Turnover0.00%IV6.44%PremiumDec 20, 2024Expiry Date2.37Intrinsic Value100Multiplier-1DDays to Expiry1.15Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma6.27Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Summit Therapeutics Stock Discussion
$Nxu Inc (NXU.US)$ grab some on your way out.
After the dual-antibody drug data from Summit Therapeutics (SMMT.US) defeated the "drug king", it was listed as Citigroup's preferred stock and the target price was raised.
No comment yet